Winslow Evans & Crocker’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Winslow Evans & Crocker’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-630	Closed	-$44K	–	1183
2019 Q4	$44K	Hold	630	–	–	0.01%	525
2019 Q3	$66K	Hold	630	–	–	0.02%	460
2019 Q2	$60K	Sell	630 -11	-2%	-$766	0.02%	479
2019 Q1	$60K	Hold	641	–	–	0.02%	465
2018 Q4	$36K	Hold	641	–	–	0.01%	521
2018 Q3	$78K	Hold	641	–	–	0.02%	414
2018 Q2	$66K	Hold	641	–	–	0.02%	448
2018 Q1	$83.1K	Hold	641	–	–	0.03%	386
2017 Q4	$62.3K	Buy	641 +516	+413%	+$69.3K	0.02%	455
2017 Q3	$18.4K	Buy	+125	New	+$23.5K	0.01%	683

Other funds holding SYRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Winslow Evans & Crocker's SYRS Position: Q1 2020 in Review

Winslow Evans & Crocker sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2020, closing a stake of 630 shares — an estimated $44K sold.

Winslow Evans & Crocker first reported a position in SYRS in Q3 2017 and held it in 10 quarters. The position peaked at $83.1K in Q1 2018. 64 funds tracked by Wall St. Rank hold SYRS as of Q1 2020.

Winslow Evans & Crocker reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
Winslow Evans & Crocker sold 630 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2020, an estimated $44K.
Winslow Evans & Crocker first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 10 quarters.
Winslow Evans & Crocker's Syros Pharmaceuticals, Inc. Common Stock position peaked at $83.1K in Q1 2018.
64 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2020.

Based on Winslow Evans & Crocker's 13F filing for Q1 2020, filed 20 Apr 2020.